{
    "clinical_study": {
        "@rank": "92434", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6"
            }
        ], 
        "brief_summary": {
            "textblock": "A cohort study to Evaluate the contraceptive effectiveness of Sino-implant (II) during the\n      3rd and 4th years of use in Chinese women"
        }, 
        "brief_title": "Contraceptive Effectiveness of Sino-implant (II) in China", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Contraception", 
        "detailed_description": {
            "textblock": "A Study to Evaluate the Contraceptive Effectiveness during the Third, Fourth and Fifth Year\n      of Sino-implant (II)Use and the Pharmacokinetics (PK) over Five Years of use in Chinese\n      Women\n\n      Population: A total of 590 Chinese Sino-Implant (II) users between 20and 44 years of age\n      enrolled in one of four prospective cohorts:\n\n      Cohort 1: n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6\n      months Cohort 2:n=20 women with insertion dates 9-11 months prior to enrollment and followed\n      for 2-6 months Cohort 3: n=250 women with insertion dates 21-24 months prior to enrollment\n      and followed through month 36 Cohort 4:n=300 women with insertion dates 33-36 months prior\n      to enrollment and followed through month 6\n\n      Study Duration: 33 total months in the field: 3 months of participant recruitment(all\n      cohorts); up to 27 months of pregnancy monitoring and PK blood sampling in Cohort 4 (up to\n      15 months in Cohort 3 and 6 months in Cohort 1 and Cohort 2);and 3 months of close-out\n      activities.\n\n      For secondary PK outcomes, blood samples will be taken 2 to 6 months apart from each woman\n      in Cohort 1 and Cohort 2; at enrollment, month 30 and month 36 from the first 20 consenting\n      women in Cohort 3; and at enrollment and months 42, 48, 54, and 60 from the first 30\n      consenting women in Cohort 4.\n\n      Primary Objective: To evaluate the contraceptive effectiveness of Sino-implant (II) during\n      the third and fourth years of use\n\n      Secondary Objectives:\n\n        1. To evaluate the contraceptive effectiveness of Sino-implant (II) during the fifth year\n           of use.\n\n        2. To characterize the total and free levonorgestrel (LNG) plasma concentration-time\n           profiles over five years following Sino-implant (II) insertion\n\n        3. To characterize the sex hormone binding globulin (SHBG) serum concentration-time\n           profile and its relationship to total LNG levels over five years following Sino-implant\n           (II) insertion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a confirmed Sino-implant (II) set in place;\n\n          -  Have a confirmed contraceptive implant insertion date consistent with the criteria\n             for the cohort she is to be enrolled in;\n\n          -  Be aged between 20 and 44 years, inclusive;\n\n          -  Not wish to become pregnant in the next year;\n\n          -  No desire to get implant removal within the next year;\n\n          -  Be able to understand the information given to them and to make personal decisions on\n             whether to participate or not in the study;\n\n          -  Consent to participation and sign an informed consent form;\n\n          -  Agree and be able to return to the clinic for follow-up visit(s).\n\n        Exclusion Criteria:\n\n          -  Acute liver disease or cirrhosis by self-report;\n\n          -  Benign or malignant tumor of the liver by self-report;\n\n          -  Use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital,\n             carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products\n             containing St. John's wort (Hypericum perforatum) by self-report;7\n\n          -  Use of medications containing LNG or other hormones that impact LNG or SHBG\n             disposition, e.g. treatment with LNG or oral contraceptives for bleeding disturbances\n             by self-report;\n\n          -  Known HIV-positive status by self-report;\n\n          -  Any condition (social or medical) which in the opinion of the Investigator would make\n             study participation unsafe, would interfere with adherence to study requirements, or\n             complicate data interpretation."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Study Population:  Women who have received contraceptive implants from the Tongxiang, An\n        Yang,  Lingbao, and Lushi  Family Planning Service Stations."
            }
        }, 
        "enrollment": {
            "#text": "539", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936454", 
            "org_study_id": "458241-1"
        }, 
        "intervention_browse": {
            "mesh_term": "Contraceptive Agents"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anyang", 
                        "country": "China"
                    }, 
                    "name": "An Yang Population and Family Planning Service Station"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lingbao", 
                        "country": "China"
                    }, 
                    "name": "Lingbao Population and Family Planning Service"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lushi", 
                        "country": "China"
                    }, 
                    "name": "Lushi Family Planning Technical Service Station"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Shanghai Institute of Planned Parenthood"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tongxiang", 
                        "country": "China"
                    }, 
                    "name": "Tongxiang Population and Family Planning Service Station"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "4", 
        "official_title": "A Study to Evaluate the Contraceptive Effectiveness During the Third, Fourth and Fifth Year of Sino-implant (II) Use and the Pharmacokinetics Over Five Years of Use in Chinese Women", 
        "overall_official": {
            "affiliation": "FHI 360", 
            "last_name": "Markus Steiner, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pregnancy Pearl Index (number of pregnancies per 100 woman-years) during the third and fourth years of use, respectively, in Cohort 3 and Cohort 4", 
            "measure": "Pregnancy Pearl Index", 
            "safety_issue": "No", 
            "time_frame": "27 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pregnancy Pearl Index during the fifth year of Sino implant (II) use", 
                "safety_issue": "No", 
                "time_frame": "27 months"
            }, 
            {
                "measure": "Total and free LNG plasma concentrations measured by a high-performance liquid chromatography with mass spectrometry assay", 
                "safety_issue": "No", 
                "time_frame": "27 months"
            }, 
            {
                "measure": "Serum SHBG concentrations measured by a chemiluminescence immunoassay", 
                "safety_issue": "No", 
                "time_frame": "27 months"
            }
        ], 
        "source": "FHI 360", 
        "sponsors": {
            "collaborator": {
                "agency": "Bill and Melinda Gates Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FHI 360", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}